Garzón Magda, García-Fructuoso Gemma, Suñol Mariona, Mora Jaume, Cruz Ofelia
Department of Neurosurgery, Hospital Sant Joan de Déu, University of Barcelona, Passeig St. Joan de Déu, 2, 08950, Esplugues de Llobregat, Barcelona, Spain,
Childs Nerv Syst. 2015 Sep;31(9):1447-59. doi: 10.1007/s00381-015-2800-9. Epub 2015 Jul 9.
In pediatric population (0-18 years), low-grade gliomas (PLGG) are the most frequent brain tumors and majority are amenable for surgical removal.
A retrospective review of 198 children diagnosed with PLGG between 1980 and 2010 at HSJD was carried out. Several variables were studied to find prognostic factors related to the outcomes (progression-free survival (PFS) and overall survival (OS)).
Median age at onset was 88.8 months (3.1 to 214.5 months, SD 53). Surgery was performed in 175 patients (88.4%), achieving gross total resection (GTR) in 77 (44%), subtotal resection (STR) in 87 (49.7%), and 11 (6.3%) biopsies. Pathological review classified 84 tumors as WHO grade I (48%) and 89 as grade II (50.8%). Adjuvant therapy (AT) was given to 75 patients (37.9%), radiotherapy in 24 (12.1%), chemotherapy in 33 (16.7%), and combined in 18 (9.1%). Sixteen patients (8.1%) died, 89 (43.4%) are alive with no evidence of disease, and 93 (47%) alive with disease, median follow-up 65.2 months. Outcome is significantly correlated with age (p = 0001, worse OS for patients younger than 12 months) and extent of tumor resection (p < 0001). OS for GTR/STR/biopsy was >200, 154.3, and 101.9 months, respectively. Patients treated with AT presented worse OS/PFS (p < 0.001) than those not treated. Histology was non significantly related to outcomes.
In our series of PLGG, the best prognostic markers are tumor location (cerebellar) and the extent of tumor resection (GTR). Infants and patients who require adjuvant therapy because of tumor progression or recurrence have worse outcome.
在儿童人群(0 - 18岁)中,低级别胶质瘤(PLGG)是最常见的脑肿瘤,大多数适合手术切除。
对1980年至2010年间在HSJD诊断为PLGG的198名儿童进行了回顾性研究。研究了几个变量以寻找与预后(无进展生存期(PFS)和总生存期(OS))相关的预后因素。
发病时的中位年龄为88.8个月(3.1至214.5个月,标准差53)。175例患者(88.4%)接受了手术,其中77例(44%)实现了全切(GTR),87例(49.7%)次全切(STR),11例(6.3%)活检。病理检查将84例肿瘤分类为WHO I级(48%),89例为II级(50.8%)。75例患者(37.9%)接受了辅助治疗(AT),24例(12.1%)接受放疗,33例(16.7%)接受化疗,18例(9.1%)接受联合治疗。16例患者(8.1%)死亡,89例(43.4%)无疾病证据存活,93例(47%)带瘤存活,中位随访65.2个月。预后与年龄(p = 0.001,12个月以下患者的OS较差)和肿瘤切除范围(p < 0.001)显著相关。GTR/STR/活检患者的OS分别为>200、154.3和101.9个月。接受AT治疗的患者的OS/PFS比未接受治疗的患者差(p < 0.001)。组织学与预后无显著相关性。
在我们的PLGG系列中,最佳预后标志物是肿瘤位置(小脑)和肿瘤切除范围(GTR)。因肿瘤进展或复发而需要辅助治疗的婴儿和患者预后较差。